• Circulating UAG impairs markers of neurogenesis and plasticity
Introduction

Results and discussion
To assess whether UAG regulates adult NSPC plasticity in the sub-granular zone (SGZ) we analyzed the effect of peripherally administered UAG for seven-days in wild-type (WT) and GOAT-null (GOAT -/-) mice 17 . GOAT -/-mice lack circulating acyl-ghrelin but have elevated levels of UAG making them ideally suited to assessing the loss of acyl-ghrelin coupled with increased plasma UAG 22 . Surprisingly, UAG-treated WT mice showed a significant 40% decrease in Ki67 + proliferating cells in the SGZ of the DG compared to vehicle-treated mice (Fig.1a,b) . Similarly, genetic blockade of acyl-ghrelin signaling in GOAT -/-mice reduced the number of dividing Ki67 + progenitor cells in the SGZ (Fig.1a,b ).
These findings were accompanied by a significant reduction in the number of doublecortin positive (Dcx + ) immature neurons within the SGZ of both UAG-treated WT and GOAT -/-mice (Fig.1c,d ). Interestingly, UAG did not further exacerbate the reduction in proliferating cells and immature neurons in GOAT -/-mice, suggesting that UAG's effect on neurogenesis may be via a saturable mechanism. While UAG is often considered inactive reports of UAG opposing acyl-ghrelin function on hepatocyte gluconeogenesis 23 , blocking acyl-ghrelin induced food intake 24 and suppressing activity of the GH axis 25 , provide support for our findings. Together, these data suggest that the striking decrease in hippocampal cell proliferation and neurogenesis is due to elevated UAG, rather than simply loss of acyl-ghrelin.
Next, we studied whether this UAG-mediated decrease in dividing progenitor SGZ cells reduced the survival of new adult-born DG neurons. To achieve this, mice in the above study received an injection of BrdU to birth-date proliferating cells on day 2 of the infusion prior to brain dissection and immunochemical analysis on day 7. The number of surviving immature neurons (BrdU + /Dcx + ) was significantly reduced in GOAT -/-mice (Fig.1g,h and Fig.S1b) . Interestingly, we also demonstrated a significant reduction in the survival of new adult-born non-neuronal cells (BrdU + /Dcx -) in UAG-treated WT mice and in vehicle-treated GOAT -/-mice, relative to vehicle-treated WT mice (Fig.1g,i ).
Analysis of a second mouse model with genetic deletion of GOAT 18 revealed a similar reduction in DG neurogenesis (Fig.S3a-d) . Importantly, genetic deletion of GOAT (in either knockout model) did not affect the number of type II stem cells (Sox2 + ) in the SGZ (Fig.S1c,e and Fig.S3e,f) , suggesting that the reduction in dividing progenitors was not due to a reduced stem cell pool but by modulation of the adult neurogenic niche. In addition, circulating immune factors implicated in reduced AHN, including eotaxin, fractalkine, IL-6, IL-10, RANTES and TNF-a, were not altered in GOAT -/-mice (Fig.S2 ).
These data identify GOAT-mediated acylation of ghrelin as a novel and important regulator of AHN.
Our findings are notable as we show that ghrelin -/-mice, which lack both acyl-ghrelin and UAG, do not have impairments in basal adult neurogenesis. Previously, the rate of cell proliferation and neuronal differentiation was reported as being reduced in ghrelin -/-mice 26 . However, our analyses of hippocampal NSPC number (Sox2), cell proliferation (Ki67), immature neuron number (Dcx) and new adult-born neuron number (BrdU/NeuN), show no change compared to wild-type mice (Fig.S4 ). These data from ghrelin -/-mice are consistent with the loss of both the pro-neurogenic acyl-ghrelin and the anti-neurogenic UAG resulting in no net change in AHN. In contrast, GOAT -/-mice lack acyl-ghrelin but have high levels of UAG, suggesting that high UAG is responsible for reduced AHN rather than the loss of acyl-ghrelin.
Next, we assessed whether elevation of UAG disrupted other molecular signatures of DG impairment. Indeed, we observed a significant reduction in immuno-labeling of the immediate early gene, c-Fos, in both UAG treated WT (58%) and GOAT -/-(44%) mice (Fig.1e,f) . Given the role of c-Fos in neural plasticity and memory consolidation [27] [28] [29] we reasoned that hippocampal-dependent learning and memory may be impaired in these mice. To determine whether the neurochemical deficits observed in GOAT -/-mice resulted in memory impairments and whether this could be rescued by acyl-ghrelin, adult WT and GOAT -/-mice were given daily injections of either saline or acyl-ghrelin for one or seven days prior to analysis of hippocampal-dependent spatial memory using a Y-maze ( Fig.S3a-d) . GOAT -/-mice displayed a deficit in performance that was unaffected by injection of acyl-ghrelin 1h prior to testing (Fig.2a) . However, treatment with acyl-ghrelin for seven days rescued the memory deficit in GOAT -/-mice (Fig.2b) . Interestingly, this enhancement in spatial memory performance remained partially intact when the mice were tested on day 28, 21 days following the end of treatment (Fig.2c) . The long-term rescue of spatial memory, long after acyl-ghrelin has cleared the circulation, is consistent with acyl-ghrelin-mediated AHN 16 . Further work using behavioral tests that place emphasis on distinguishing similar but distinct spatial contexts is required to fully elucidate the consequences of reduced AHN in GOAT -/-mice. However, these data are consistent with our neurochemical findings and demonstrate that GOAT is essential for hippocampal-dependent spatial memory.
Mechanistically, we reasoned that as circulating levels of acyl-ghrelin and UAG have opposing actions on neurogenesis and cognition in mice, there should be a reduction in the plasma ratio of acyl-ghrelin to UAG (AG:UAG) in humans diagnosed with dementia. As acyl-ghrelin protects against neuron loss in models of Parkinson's disease (PD) 30, 31 and is reportedly reduced in human PD 32, 33 , we hypothesized that circulating AG:UAG ratios C.
30m may be particularly affected in individuals diagnosed with PD dementia (PDD) compared to a cognitively-unimpaired PD group. To test this hypothesis, we recruited individuals with PD, PDD and age-matched healthy controls to determine fasting and post-prandial levels of both acyl-ghrelin and UAG. In keeping with our pre-clinical findings, we found that the plasma ratio of AG:UAG was significantly reduced in the PDD group compared to the cognitively intact PD and control cohorts (Fig.3a,b) . Consistent with this finding, cognitive impairment was correlated with a reduction in plasma AG:UAG (Fig.3c ),
suggesting this ratio as a potential novel diagnostic biomarker for human dementia.
Interestingly, the cognitively intact PD group did not show reduced acyl-ghrelin levels in either the fasted or 180 minutes after eating (Table S1 ), further supporting a specific role for ghrelin in regulating mnemonic function. To the best of our knowledge this is the first study of ghrelin in PD to perform stratification of patients by cognitive ability. Notably, there is impaired hippocampal plasticity, including neurogenesis, in rodent toxin-based and genetic-based models of PD [34] [35] [36] , whilst post-mortem human PDD brain have reduced numbers of NSPCs and immature neurones in the adult DG 11 . Moreover, PD patients display impaired performance in the Object Pattern Separation task which is consistent with impaired DG function and possibly reduced AHN 37 . Combined, these studies provide a putative mechanistic link between AG:UAG ratio, AHN and PDD in humans.
Together, our findings demonstrate a previously unknown function for UAG and GOAT in reducing neurogenesis and spatial memory performance, and suggest that enhancing circulating acyl-ghrelin, or more importantly, increasing the AG:UAG ratio may ameliorate cognitive decline. To the best of our knowledge this is the first description of a post-translational modification to a circulating factor that modulates, in either direction, neurogenesis and cognition.
Methods
Study approval
The This GOAT -/-line was generated using Velocigene technology. The GOAT gene sequence (ATG-stop) was replaced with a lacZ reporter gene using the target vector, bacterial artificial chromosome (BAC). These mice originated from C57BL/6/129 targeted embryonic stem cells and mice were backcrossed onto a C57BL/6 mice background. Mice were kept in standard laboratory conditions at Monash University with free access to food (chow diet, cat no. 8720610 Barastoc stockfeeds, Victoria Australia), and water at unless otherwise stated.
UAG infusion
Each mouse 17 was fitted with an indwelling jugular vein catheter connected to a subcutaneous osmotic mini-pump (ALZET model 1007D) primed to deliver vehicle (sterile isotonic saline containing BSA (1mg/ml) and heparin (5U/ml) at 0.5µl/h) or UAG (48ug/day) under isoflurane anesthesia. One day later all mice received an injection of thymidine analogue, BrdU (50mg/kg i.p), to label dividing cells. After seven days mice were re-anesthetized and killed by decapitation, the brains being excised whole and processed for immunohistochemistry (IHC) as described below. For immunofluorescent analysis of Sox2, sections were treated as above with the exception of antigen retrieval being performed in sodium citrate at 70°C for 1h (rather than 2N HCl or borate buffer) with subsequent blocking in 5% NGS. Immunoreactivity was detected using rabbit anti-Sox2 (1:500, ab97959, Abcam) and goat anti-rabbit AF-568 (Life Technologies, USA). Nuclei were counterstained with Hoechst prior to mounting as described above. Immunoreactivity and tissue processing was performed as described above.
Quantification of labeled cells
Immuno-stained brain tissue was imaged by light microscopy (Nikon 50i) (for DAB), fluorescent (Axioscope, Zeiss) or confocal microscopy (LSM710 META, Zeiss).
Immunolabelled cells were manually counted bilaterally through the z-axis using a ×40
objective and throughout the rostro-caudal extent of the granule cell layer (GCL).
Resulting numbers were divided by the number of coronal sections analyzed and multiplied by the distance between each section to obtain an estimate of the number of cells per hippocampus (and divided by 2 to obtain the total per DG). For quantification of DG volume, Hoechst nuclear stain was used on tissue sections as above and fluorescent area expressed as μm 2 per section. Images were processed using Zen (Zeiss) or Image J software. All analyses were performed blind to genotype and treatment.
Milliplex plasma analysis.
Mouse plasma was analyzed using the Milliplex-MAP 6-plex mouse cytokine magnetic bead panel kit (Cat #SPR402) , to analyze the cytokines IL-6, eotaxin, fractakine, IL-10, RANTES and TNFα. The assay was performed according to the manufacturer's guidelines.
All reagents were brought to room temperature (RT) before use in the assay. Plasma samples were thawed at 4˚C and diluted 1:2 with assay buffer. Antibody-immobilized beads were sonicated for 30 seconds and vortexed for 1 minute. 60µl from each antibodybead vial was added to the mixing bottle provided and the final volume made up to 3ml with assay buffer. Wash buffer (WB) was prepared by mixing 60ml 10X WB with 540ml deionized water. Serum matrix solution was prepared by adding 2ml assay buffer to the lyophilized serum matrix. Subsequently, the mouse cytokine standard cocktail (Cat #MXM8070) was reconstituted with 0.25ml deionized water and a 1:5 serial dilution was made.
WB (200µl) was added to each well of the 96-well plate before it was sealed and agitated for 10 minutes at room temperature. The WB was removed and 25µl of each standard or control was added to the appropriate wells and 25µl of assay buffer to the sample wells.
Next, 25µl of serum matrix was added to the background, standards and control wells, and 25µl of diluted plasma sample was added into the sample wells. Following this, the mixing bottle containing the antibody-bead mixture was vortexed and 25µl was added to each well. The plate was sealed, wrapped in foil and incubated at 2-8˚C on a plate shaker for 16-18 hours.
After incubation, the well contents were removed (using a handheld magnet) and the 
Behavioral testing
To determine whether the neurochemical deficits observed in GOAT -/-mice resulted in impaired hippocampal-dependent spatial memory and whether this could be rescued by acyl-ghrelin, adult 12 week-old WT and GOAT -/-mice (n=6/group) were given daily injections of either saline or acyl-ghrelin (300μg/kg i.p) for 1 or 7 days prior to analysis of spatial memory using a Y-maze. This dose of acyl-ghrelin was chosen as it has previously been shown to increase food intake. Injections were performed daily between 9-10am when mice were in a fed state. A modified Y-maze task was used to assess spatial memory performance on day 1, 7 or 28 days after the first acyl-ghrelin injection. All tests were performed in an experimental room with sound isolation and dim light. The animals were carried to the test room for at least 1 hour of acclimation. Behavior was monitored using a video camera positioned above the apparatuses and the videos were later analyzed by an experienced blinded researcher using video tracking software (CleverSys Inc, Reston, VA, USA). The modified Y-maze measures spatial memory, as spatial orientation cues facilitate rodents to explore a novel arm rather than returning to a previously visited arm. We used a Y-shaped grey Perspex maze (30 cm x 10 cm x 16 cm) and each arm could be isolated by blocking entry with a sliding door. Saw dust from a mouse's home cage lined the maze during the trials and extra maze cues on the walls were placed 30-40 cm from the end of the arms to provide spatial orientation cues. Behavior was tested across two trials, the first of which had one arm of the maze randomly blocked off. Mice were allowed to explore the reduced maze for 10 minutes and then returned to their home cage. The second trial was conducted 30 minutes after the first trial and both arms of the maze were opened. Mice were placed in the start arm and allowed to explore the full maze for 5 minutes. All behaviors were recorded and analyzed using tracking software. Novel arm exploration was recorded when all four feet of each mouse entered the novel arm. The apparatus was cleaned with 80% ethanol between each trial and each animal.
Human plasma collection
All procedures involving human participants were performed at the Clinical Ageing Blood samples for assessing acyl-ghrelin were treated with 4-(2-Aminoethyl)-benzenesulfonyl fluoride to prevent de-acylation and analyzed using a multiplex assay (Millipore). Total ghrelin was analyzed by ELISA (Millipore). Area under the curve (AUC) was calculated for each analyte. Three outliers were identified using the ROUT test (Q=1%) and removed prior to analysis using a Kruskall-Wallis test with Dunn's post-hoc multiple comparison.
Statistical analysis
Statistical analyses were carried out using GraphPad Prizm 6.0 for Mac. Data distribution were assessed using the Schapiro-Wilks normality test. For normally-distributed data, comparisons between two groups was assessed by two-tailed unpaired Student's t-test.
For multiple groups with one variable factor, a one-way ANOVA was used, and where there were two variable factors a two-way ANOVA was used. Appropriate post-hoc tests were used as described. Data displaying non-Gaussian distribution were analyzed by non-parametric tests, as described in the text. Spearman correlation (two-tailed) and linear regression analysis were used to determine the goodness-of-fit between plasma AG:UAG (AUC) and cognition (MoCA). Data are presented as mean ± sem. *, P < 0.05; **, P < 0.01; ***, P < 0.001 were considered significant. . GOAT -/-mice, generated by Yang et al. 17 , have a reduced rate of cell proliferation (A,B) and neurogenesis (C,D) in the hippocampal DG. However, NSPC (Sox2 + ) number in the SGZ of the hippocampal DG is similar between WT and GOAT -/-mice (E,F). Statistical analysis was performed by two-tailed Students t-test. Scale bar = 200μm. *P<0.05. All data shown are mean ± SEM. n = 6 mice/group. 
